KemPharm (NASDAQ:KMPH) Upgraded by Zacks Investment Research to Hold

KemPharm stock has undergone multiple analysts rating changes in the recent past.  KemPharm Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of KemPharm traded up $0.03 on Wednesday, reaching $9.76. 100 shares of the stock traded hands, compared to its average volume of 389755. Shares of KemPharm were trading at $9.76 on Wednesday. The firm’s 50 day moving average is $9.24 and its 200 day moving average is $9.88.KemPharm has a 12 month low of $9.52 and a 12 month high of $22.08. While on yearly highs and lows, KemPharm’s today has traded high as $10.01 and has touched $9.52 on the downward trend. See More Analyst Rating at: RATING

KemPharm Earnings and What to expect: 

KemPharm last posted its quarterly earnings data on August 12th, 2021. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.63. The firm had revenue of $11.99 million for the quarter, compared to analyst estimates of $12.10 million. KemPharm has generated ($3.00) earnings per share over the last year. Earnings for KemPharm are expected to decrease in the coming year, from ($0.03) to ($0.13) per share. KemPharm has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for KemPharm are expected to decrease in the coming year, from ($0.03) to ($0.13) per share. The P/E ratio of KemPharm is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of KemPharm is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

KemPharm (NASDAQ:KMPH) Moving Average Technical Analysis

5 day Moving Average is $9.23 And 5 day price change is $1.02 (11.67%)  with average volume for 5 day average is 244,620. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $9.11 and 20 day price change is $0.94 (10.66%) and average 20 day moving volume is 376,125. 50 day moving average is $9.24  and 50 day price change is -$0.13 ( -1.31%)  and with average volume for 50 days is : 425,224. 200 day moving average is $9.88  and 200 day price change is -$4.71 (-32.55%)  and with average volume for 200 days is : 1,834,687.

Other owners latest trading in KemPharm :

  • On 9/17/2021 shares held by Virtu Financial LLC were 71,435 which equates to market value of $0.92M and appx 0.10% owners of KemPharm
  • On 8/25/2021 shares held by Marshall Wace LLP were 17,153 which equates to market value of $0.22M and appx 0.00% owners of KemPharm
  • On 8/23/2021 shares held by Morgan Stanley were 21,234 which equates to market value of $0.27M and appx 0.00% owners of KemPharm
  • In total Institutional ownership equates to Institutional Ownership Percentage: 21.73% for KemPharm

See More Analyst Rating at: RATING